ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Cut to $32.00 by Analysts at Royal Bank Of Canada

Royal Bank Of Canada has reduced its price target for ACADIA Pharmaceuticals from $34.00 to $32.00 while maintaining an "outperform" rating. This suggests a potential upside of 49.95% from the previous close. Other analysts have varied opinions, with ratings ranging from Strong Buy to Sell. ACADIA's stock performance shows a recent trading price of $21.34, with a market cap of $3.60 billion. The company reported $0.42 EPS for the last quarter, exceeding estimates, and has set FY 2025 guidance at EPS of 0.7.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) had its price target dropped by research analysts at Royal Bank Of Canada from $34.00 to $32.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an "outperform" rating on the biopharmaceutical company's stock. Royal Bank Of Canada's target price would suggest a potential upside of 49.95% from the company's previous close.

Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves

A number of other research analysts also recently commented on ACAD. Wall Street Zen downgraded ACADIA Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, September 5th. UBS Group upped their price target on ACADIA Pharmaceuticals from $36.00 to $39.00 and gave the stock a "buy" rating in a research note on Tuesday, September 9th. The Goldman Sachs Group raised their price objective on ACADIA Pharmaceuticals from $15.00 to $17.00 and gave the company a "sell" rating in a research note on Thursday, August 7th. Needham & Company LLC boosted their target price on ACADIA Pharmaceuticals from $28.00 to $29.00 and gave the stock a "buy" rating in a report on Thursday. Finally, JPMorgan Chase & Co. lowered their price target on ACADIA Pharmaceuticals from $34.00 to $33.00 and set an "overweight" rating on the stock in a report on Monday, September 29th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, ACADIA Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $28.94.

Get ACADIA Pharmaceuticals alerts:

Get Our Latest Stock Analysis on ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Stock Performance

Shares of NASDAQ:ACAD traded down $0.99 during trading hours on Thursday, hitting $21.34. 385,179 shares of the company's stock traded hands, compared to its average volume of 2,152,248. The company's fifty day simple moving average is $22.78 and its two-hundred day simple moving average is $21.84. The company has a market cap of $3.60 billion, a price-to-earnings ratio of 16.05, a price-to-earnings-growth ratio of 7.90 and a beta of 0.80. ACADIA Pharmaceuticals has a 52 week low of $13.40 and a 52 week high of $26.65.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.42 earnings per share for the quarter, topping analysts' consensus estimates of $0.14 by $0.28. The firm had revenue of $278.63 million for the quarter, compared to analysts' expectations of $276.52 million. ACADIA Pharmaceuticals had a return on equity of 14.69% and a net margin of 21.80%.ACADIA Pharmaceuticals's revenue was up 11.3% on a year-over-year basis. During the same quarter last year, the business posted $0.20 EPS. ACADIA Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts anticipate that ACADIA Pharmaceuticals will post 0.7 EPS for the current fiscal year.

Insider Activity at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 3,498 shares of the company's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $23.65, for a total transaction of $82,727.70. Following the completion of the sale, the executive vice president owned 43,447 shares in the company, valued at approximately $1,027,521.55. The trade was a 7.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Elizabeth A. Garofalo sold 1,600 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $25.98, for a total value of $41,568.00. Following the completion of the transaction, the director directly owned 25,382 shares in the company, valued at $659,424.36. The trade was a 5.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 27,098 shares of company stock valued at $678,256. 26.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Geneos Wealth Management Inc. grew its position in shares of ACADIA Pharmaceuticals by 113.0% in the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 756 shares during the period. Banque Transatlantique SA acquired a new stake in shares of ACADIA Pharmaceuticals in the 1st quarter valued at about $31,000. Picton Mahoney Asset Management bought a new stake in shares of ACADIA Pharmaceuticals in the first quarter valued at about $32,000. Smartleaf Asset Management LLC boosted its position in shares of ACADIA Pharmaceuticals by 107.0% during the third quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company's stock worth $36,000 after buying an additional 885 shares during the period. Finally, Federated Hermes Inc. grew its holdings in shares of ACADIA Pharmaceuticals by 231.5% during the first quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company's stock worth $38,000 after buying an additional 1,618 shares in the last quarter. Institutional investors and hedge funds own 96.71% of the company's stock.

About ACADIA Pharmaceuticals

(Get Free Report)

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

Should You Invest $1,000 in ACADIA Pharmaceuticals Right Now?

Before you consider ACADIA Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.

While ACADIA Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here